Proteomics for the study of new biomarkers in Fabry disease: State of the art
- PMID: 33077353
- DOI: 10.1016/j.ymgme.2020.10.006
Proteomics for the study of new biomarkers in Fabry disease: State of the art
Abstract
Nephropathy represents a major complication of Fabry Disease and its accurate characterization is of paramount importance in predicting the disease progression and assessing the therapeutic responses. The diagnostic process still relies on performing renal biopsy, nevertheless many efforts have been made to discover early reliable biomarkers allowing us to avoid invasive procedures. In this field, proteomics offers a sensitive and fast method leading to an accurate detection of specific pathological proteins and the discovery of diagnostic and prognostic biomarkers that reflect disease progression and facilitate the evaluation of therapeutic responses. Here, we report a review of selected literature focusing on the investigation of several proteomic techniques highlighting their advantages, limitations and future perspectives in their application in the routine study of Fabry Nephropathy.
Keywords: Anderson-Fabry disease; Biomarkers; Clinical proteomics; Fabry nephropathy; Mass spectrometry; Matrix-assisted laser desorption/ionization.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest H.P.M. reports receiving grants from Alexion, Amicus, Sanofi Genzyme, and Shire. E.S. reports receiving grants from Sanofi Genzyme; positions on the advisory boards of Amicus and Sanofi Genzyme; speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.Pi. reports participation at advisory boards, speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.R., V.L., A.S., M.M.B., F.M. and F.Pa. declare no conflict of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical